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Background: Polycystic ovary syndrome (PCOS) is associated with reduced quality of life 
(QoL), though the role of associated obesity is unclear. In this study we examined the effects 
of six months treatment with liraglutide, 1.8mg od, on obesity, depression and QoL in young 
women with PCOS and obesity compared to age- and weight-matched controls.  
Methods: In a cross-sectional study, thirty six women were recruited (19 PCOS, 17 controls), 
age 33.9 ±6.7 vs. 33.5 ±7.1yr, and weight 102.1 ±17.1 vs. 100.4± 15.1kg, respectively. PCOS 
was diagnosed according to the Rotterdam criteria. Depression was measured using the 
Centre for Epidemiologic Studies Depression Scale (CES-D). QoL was measured using the 
World Health Organisation QoL questionnaire (WHOQOL-BREF). 
Results: At baseline there was no difference in QoL or CES-D scores between the two groups. 
At six months, weight was reduced by 3.0 ±4.2kg, P= 0.01, in the PCOS group and 3.8 ±3.4kg, 
P= 0.001, in controls. Psychological health improved in the PCOS group (percentage change 
11.3%, p<0.02). Combining the two groups revealed significant improvement (P<0.05) in 
physical (82.6 ±11.2 vs. 78.9 ±13.6), psychological (62.4 ±16.5 vs. 57.5 ±16.4) and social health 
(76.6 ±15.3 vs. 71 ±16.8) components of the WHOQOL-BREF at 6 months.  
Conclusions: Weight loss is associated with an improvement in QoL; and when matched for 
age and obesity, PCOS was not independently associated with reduced QoL or depression.  
Key words: PCOS; Liraglutide; Obesity; Quality of life; Depression.   
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1. Introduction 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of 
reproductive age [1]. PCOS is associated with conditions that may have a negative impact on 
quality of life (QoL) including hirsutism, oligomenorrhoea, obesity and sub-fertility. While 
PCOS has been associated with depression and reduced QoL in several studies [2, 3, 4], it is 
not yet clear which of its components has the main effect. Obesity is seen in up to 78% of 
women with PCOS [5] and is associated with reduced Qol [6]. Despite its high prevalence, only 
a few studies have accounted for obesity when examining the psychological health in women 
with PCOS and their results are not conclusive [7, 8]. In addition, the effects of weight loss on 
QoL in women with PCOS and obesity are not yet clear.  
Liraglutide is a glucagon like peptide-1 analogue which causes weight loss and it represents 
an attractive option for the treatment of obesity in women with PCOS [9]. 
The primary aim of this study was to determine the effect of 6 months treatment of liraglutide 
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2. Study design   
Interventional case-control study of young women with PCOS and obesity, and age- and 
weight-matched controls. The study was approved by the Leeds (East) Research Ethics 
Committee and informed consent was given by all study participants before participation; 
clinical trial registration number: ISRCTN48560305. 
 
3. Methods 
Women with PCOS were recruited from the endocrine clinic and controls were recruited 
through an advertisement in the local newspaper. Women with PCOS and controls were 
invited for a screening visit if they had a body mass index (BMI) between 30–45 kg/m2, and 
were between 18–45 years of age. PCOS was diagnosed according to the Rotterdam criteria 
[10]. Other endocrine disorders with similar presentation were excluded. Control subjects 
underwent the same biochemical screening as the PCOS group to exclude any unknown 
endocrine disorder. Control subjects with a history of clinical or biochemical 
hyperandrogenism or menstrual irregularities were excluded. Study exclusion criteria 
included previous history of hypothyroidism, pancreatitis, heart failure, renal failure, type 2 
diabetes, alcohol consumption of >14 units/week, and pregnant or breast feeding women.   
Participants, PCOS and controls, who fulfilled the study inclusion/exclusion criteria were 
treated with Liraglutide 0.6 mg od for one week, 1.2mg for one week and then 1.8mg od for 
six months. Study participants did not receive any special dietary advice and were not advised 
to change their diet. Study participants were assessed at baseline and six months after 
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3.1 Anthropometric measurements 
Weight was measured in kilograms, and body mass index (BMI) was calculated as weight (in 
kg) divided by the square height (in meters). 
 
3.2 Biochemical investigations 
Venous blood samples were collected in the morning of study visits after a minimum of 10h 
fast. Serum testosterone was measured by tandem mass spectrometry and sex hormone 
binding globulin (SHBG) by an immunometric assay with fluorescence detection on the DPC 
Immulite 2000 analyzer. Free androgen index (FAI) was calculated as the total testosterone x 
100/SHBG. Serum insulin was assayed using a competitive chemiluminescent immunoassay 
performed on the manufacturer’s DPC Immulite 2000 analyzer (Euro/DPC, Llanberis, UK). 
Fasting plasma glucose (FPG) was measured using a Synchron LX 20 analyzer (Beckman-
Coulter). Insulin resistance was measured using the Homeostasis Model Assessment (HOMA) 
as HOMAIR= (FPG (mmol/L) X fasting insulin (iu/ml))/22.55) [11]. 
 
3.1 Quality of life 
QoL was measured using the short version of the World Health Organisation QoL 
questionnaire (WHOQOL-BREF), which includes 26 questions to assess four major domains 
(subscales): physical, psychological, social and environment [12]. Scores are given out of a 
hundred and higher scores are better; a score of more than 50% indicates an acceptable to 
good QoL. The WHOQOL-BREF has been shown to display high internal consistency (0.92); 
good test-retest reliability (0.66 – 0.72); discriminant validity (discriminating sick from healthy 
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people), and content validity (correlation with the Short Form 36 Health Survey (SF-36)) [12]. 
WHOQOL-BREF provides a very good holistic assessment of QoL in the general population and 
its validation study included a group of women with PCOS [12].  
 
3.2 Depression 
Depression was measured using the Centre for Epidemiologic Studies Depression Scale (CES-
D), which includes twenty items reflecting six major dimensions of depression: depressed 
mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, 
psychomotor retardation, loss of appetite, and sleep disturbance experienced in the past 
week [13]. An average score of ≥16 on this scale suggests a high risk for depression or being 
in need of treatment. CES-D has been validated and it has an internal consistency ranging 
from 0.85 to 0.90 [13]. The test-retest reliability was in the moderate range r=0.54 for tests 
repeated over a three to twelve month time interval [13]. 
 
3.3 Statistical analysis 
No priori power calculation was undertaken as data presented represent secondary outcomes 
to another study [14, 15, 16]. Post-hoc power calculations are not recommended [17]. Data 
were checked for normality using Kolmogorov-Smirnov test. Differences between groups at 
baseline were analysed using the independent t-test for continuous data (or Mann-Whitney 
U test for non-normally distributed data). Frequency distributions’ were analysed using Chi-
square test. Between groups’ comparisons after intervention were as follows: for each group 
(PCOS and controls) a percentage change from baseline to 6 months was calculated. The 
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between group differences were compared using the independent t-test (or Mann-Whitney 
U test for non-normally distributed data).  
Within groups, and combined groups analyses (baseline vs. six months) were performed using 
the dependent t-test for continuous data (or Wilcoxon signed-rank test for non-normally 
distributed data).  Data were analysed using intention to treat analysis with missing values for 
sequential data imputed by carrying the last observation forward [18]. Statistical analysis was 
performed using the PASW statistics 19 package (SPSS Inc., Chicago, USA). A two tailed P value 
of <0.05 was considered statistically significant. 
 
4. Results  
4.1 Baseline characteristic 
Thirty six women were recruited (19 PCOS, 17 controls), age 33.9 ±6.7 vs. 33.5 ±7.1yr, and 
weight 102.1 ±17.1 vs. 100.4 ±15.1kg, respectively (all P >0.05). The PCOS group, as expected, 
had higher testosterone 1.3 ±0.4 vs. 0.90 ±0.3nmol/L (P=0.01), free androgen index 4.4 ±2.0 
vs. 2.6 ±1.2 (P=0.02), insulin 22.0 ±9.4 vs. 16.1 ±5.6iu/L (P=0.03), and HOMA-IR 5.1 ±2.6 vs. 
3.5 ±1.3 (P=0.03), respectively.  
There was no significant difference between the PCOS and control groups on the CES-D with 
six (32%) vs. five (29%), respectively (P=0.8) for women having scores ≥ 16 suggestive of 
depression. Similarly, there was no difference on the WHOQOL-BREF questionnaire between 
the two groups (Table 1).  
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4.2 Intervention with liraglutide 
Twenty five women, 69%, completed the study (13 PCOS, and 12 controls). The 11 participants 
who dropped out during the study were significantly younger than those who completed the 
study 30.2 ±5.2 vs. 35.2 ±6.9 years (P= 0.04), respectively; but completers and non-completers 
did not significantly differ in their weight, BMI, QoL or depression scores at baseline, data not 
presented. Reasons for drop out were: nausea and vomiting with liraglutide (four), loss of 
follow up (four), frequently missing study drug (one), change in personal circumstances (one), 
and pregnancy (one). Following six months treatment with liraglutide weight was reduced by 
3.0 ±4.2kg (2.8%), P=0.01, in the PCOS group and 3.8 ±3.4kg (3.7%), P=0.001, in controls. 
 
4.3 QoL and depression 
There was no significant change at 6 months in the number of women who scored ≥16 on the 
CES-D questionnaire, suggestive of depression, in the PCOS group (baseline vs. 6-month): 6 
(32%) vs. 5 (26%), P=072; and controls: 5 (29%) vs. 3 (18%), P= 0.42, respectively.   
The psychological health on the WHOQOL-BREF questionnaire improved in the PCOS group at 
six months, percentage change 11.2%, P=0.02 (Table 1), however the between groups 
comparison was not significant: 95% confidence interval= -36.7 – 23.3%, P= 0.40 (Table 1). 
Scores on other components of the QoL questionnaire did not significantly differ at 6 months 
compared to baseline in either group (Table 1). 
 
 
4.4 Combined groups 
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As both groups responded equally to treatment, and there was no significant difference in 
QoL or depression scores between the PCOS and control groups at baseline, the effects of 
treatment were assessed for both groups combined. This showed significant improvement in 
physical, psychological, and social health on the WHOQOL-BREF questionnaire after 6-month 
treatment with liraglutide (Table 2). Scores on the CES-D questionnaire did not significantly 
differ at 6 months from baseline (Table 2). 
 
5. Discussion  
There was an improvement in QoL associated with weight loss for both the PCOS and control 
groups and there was no difference between the groups either at baseline or after 6 months 
when matched for age and weight. This suggests that obesity rather than the metabolic 
parameters in PCOS is the main factor driving general wellbeing in young women with PCOS 
and obesity. Our results are in accord with previous data by Alvarez-Blasco et al. [7] who 
reported similar QoL for PCOS and controls when obesity was accounted for. Conversely, 
others have reported that women with PCOS showed significantly lower life satisfaction 
compared to controls; however, in this study weight was not matched and many of study 
participants wanted fertility that is a potent cause of reduced QoL [8]. Using the PCOS health-
related quality of life questionnaire (PCOSQ) [19], it was reported that menstrual and 
hirsutism problems were the most serious concerns followed by emotional problems in 
women with PCOS whereas weight and infertility were the least important; however, this was 
performed in normal weight  women with PCOS [20]. 
Few studies have examined the impact of weight loss on QoL and depression in women with 
PCOS. In accord with our study, women with PCOS randomised to one of three 20-week 
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lifestyle programs all achieved weight loss and an improvement in QoL [21]. A similar finding 
was reported in overweight and obese women with PCOS who were randomised to low 
carbohydrate or a conventional diet for 12 months where a 4% weight loss was achieved and 
a significant improvement in QoL resulted [22]. A low-protein high-carbohydrate diet 
compared to a high-protein low-carbohydrate diet in overweight women with PCOS showed 
equal weight loss but only the high-protein diet group improved their depression scores [23]. 
The improvement in QoL observed in our study may in theory be related to liraglutide 
treatment rather than the weight loss achieved, especially as our study did not include a 
placebo treated group. However, the results reported are similar to the improvement seen in 
diet studies and there are no data to suggest that liraglutide treatment has any 
neuropsychiatric effects. It is worth noting that none of the participants in our study wanted 
to conceive and that their average scores on the WHOQOL-BREF were more than 50% 
indicating at least moderate – good QoL.   
 
6. Study limitations 
While many studies examining QoL in women with PCOS have used the PCOSQ [19], we have 
used the WHOQOL-BREF that provides a very good, more holistic assessment of QoL, and its 
validation study included women with PCOS [12]. In addition, the PCOSQ may not have 
reflected QoL well in healthy controls. While the PCOSQ does account for fertility [19], this 
was not a factor in our study. 
A study limitation is the small study sample. Whilst this was a small study there was an overall 
improvement in the Qol parameters following weight loss arguing against any type 2 error, 
though larger numbers may have detected small differences between the groups following 
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weight loss.  Combining the two groups was appropriate as there was no difference between 
the two groups at baseline or at six months in the CES-D and the WHOQOL-BREF scores. 
Another limitation is the absence of a control group aiming to achieve similar weight loss 
through diet or a physical activity; subsequently it is difficult to be sure if the changes in QoL 
observed in our study were related to Liraglutide, weight loss, or both. 
 
7. Study strengths 
We have used a validated questionnaire to assess QoL in women with PCOS and controls. 
Study participants were well matched for age and obesity, two factors that are known to be 
associated with reduced QoL [6, 24]. 
 
8. Conclusions 
PCOS was not independently associated with reduced QoL, and/or depression, in the 
presence of obesity.  Six months treatment with liraglutide resulted in significant reduction in 
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PCOS (n=19) Controls (n=17) PCOS Controls Between groups difference 





95%CI  P-value 
Weight (kg) 102.1 (17.1) 100.4 (15.1) -2.8%* -3.7%* -1.5 – 3.2 0.49 
BMI (kg/m2) 37.9 (5.0) 36.5 (4.6) -2.6%* -3.7%* -1.3 – 3.5 0.27 
WHOQOL-BREF:       
Physical health 80.4 (12.8) 77.3 (14.6) 5.4% 7.4% -13.5 – 9.5 0.49 
Psychological health 59.1 (9.7) 55.7 (21.9) 11.3* 18% -36.7 – 23.3 0.40 
Social health 73.7 (12.5) 68 (20.5) 7.4% 15.2% -24.9 – 9.3 0.85 
Environment 71.5 (12.3) 73.3 (16.9) 4.3% 8.0% -20.4 – 13 0.30 
Table 1. Anthropometric measurements and quality of life scores at baseline and after treatment with liraglutide. BMI, body mass index; WHOQOL-BREF, 
World Health Organisation quality of life questionnaire; PCOS, polycystic ovary syndrome; 95%CI, 95% confidence interval. Data are mean (standard deviation 
(SD)). 13 women with PCOS and 12 controls completed the study; intention-to-treat analysis was performed, including all study participants, with the last 
observation carried forward. *Significant within group difference, 6-month vs. baseline, P<0.05. 
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 Combined groups (n=36)* 
 Baseline 6-month P 
CES-D ≥16 11 (31%) 8 (22%) 0.42 
WHOQOL-BREF    
Physical health 78.9 ±13.6 82.6 ±11.2 0.04 
Psychological health 57.5 ±16.4 62.4 ±16.5 0.01 
Social health 71 ±16.8 76.6 ±15.3 0.01 
Environment 72.3 ±14.5 74.8 ±12.4 0.18 
Table 2. The effect of treatment with liraglutide on the CES-D and WHOQOL-BREF 
questionnaires scores for the combined groups (PCOS and controls).  A score of ≥16 on the 
Centre for Epidemiologic Studies Depression Scale (CES-D) questionnaire is suggestive of 
depression. WHOQOL-BREF, World Health Organisation Quality of Life Questionnaire. Data 
presented as mean ±standard deviation (SD) or number (percentage). *25 participants 
completed the study; intention-to-treat analysis was performed, including all 36 study 
participants, with the last observation carried forward. 
 
 
 
 
